A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A Series of Transplantable Patient-Derived Xenograft Models for Acute Myeloid Leukemia Subgroups Lacking Established Cell Lines

  • By

  • Binje Vick

  • Vindi Jurinovic

  • Kristina Kuhbandner

  • Lena Lagally

  • Lisa Latzko

  • Chiara Arnreich

  • Gerulf Hänel

  • Amelie Muth

  • Maximilian Schönung

  • Arnold Kloos

  • Maja Rothenberg-Thurley

  • Annika M. Dufour

  • Stephanie Schneider

  • Lesca M. Holdt

  • Liliana Mura

  • Fabian Klein

  • Annette Frank

  • Dhruv Mehra

  • Annika Fröhlich

  • Johannes W. Bagnoli

  • Maya C. André

  • Claudia D. Baldus

  • Martin Carroll

  • Christine Dierks

  • Martin Ebinger

  • Katharina S. Götze

  • Pablo Menéndez

  • Christian Récher

  • Ambrine Sahal

  • Jean-Emmanuel Sarry

  • Christian Thiede

  • Talía Velasco-Hernández

  • Xiaoyan Wei

  • Jan H. Klusmann

  • Wolfgang Enard

  • Michael von Bergwelt-Baildon

  • Wolfgang Hiddemann

  • Klaus H. Metzeler

  • Philipp A. Greif

  • Michael Heuser

  • Daniel B. Lipka

  • Marion Subklewe

  • Sebastian Vosberg

  • Tobias Herold

  • Karsten Spiekermann

  • Irmela Jeremias

  • October 5, 2026

Share

Clinical Report: Transplantable Patient-Derived Xenograft Models for AML

Background

Acute myeloid leukemia (AML) is a heterogeneous and aggressive hematologic malignancy with a poor prognosis due to frequent relapses after initial chemotherapy. The lack of reliable model systems has hindered the development of effective therapies. Patient-derived xenograft (PDX) models involve transplanting primary human cancer cells into immunodeficient mice, preserving the tumor's genetic and biological characteristics.

Data Highlights

No numerical data or trial results were provided in the source material.

Key Findings

  • PDX models provide insights into AML pathogenesis, therapy resistance, and clonal evolution.
  • Access to primary patient material is limited, affecting the availability of cells for repetitive assays.
  • The study included 2111 NSG mice to ensure a diverse representation of age and sex.
  • Models developed represent AML subgroups that currently lack established cell lines.
  • These models are available to the research community for further investigations.

Clinical Implications

The availability of robust PDX models for AML facilitates the exploration of therapeutic strategies and enhances understanding of disease mechanisms.

Conclusion

The development of serially transplantable PDX models for AML provides tools for studying disease biology and testing new therapies.

Related Resources & Content

  1. Blood Cancer Journal, 2015 -- A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia
  2. ASCO Publications, 2009 -- Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia
  3. ASCO Publications, 2019 -- Development and validation of a novel disease risk model for patients with AML receiving allogeneic hematopoietic cell transplantation.
  4. NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026 - PubMed
  5. ASCO Publications — Patient-Derived Xenografts for Investigation of Acquired Resistance in Oncogene-Driven Cancers: Building a Better Mousetrap
  6. Acute Myeloid Leukemia Guidelines - Hematology.org
  7. NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026 - PubMed
  8. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial - PubMed
  9. Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia
  10. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
  11. FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation | FDA
  12. Review
  13. TP53-mutated acute myeloid leukemia: how can we improve outcomes? - PubMed
  14. Impact of TP53 variants and germline mutations on allogeneic stem cell transplantation outcomes in acute myeloid leukemia and myelodysplastic neoplasms | Leukemia

Original Source(s)

A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist

  • by Binje Vick, Vindi Jurinovic, Kristina Kuhbandner, Lena Lagally, Lisa Latzko, Chiara Arnreich, Gerulf Hänel, Amelie Muth, Maximilian Schönung, Arnold Kloos, Maja Rothenberg-Thurley, Annika M. Dufour, Stephanie Schneider, Lesca M. Holdt, Liliana Mura, Fabian Klein, Annette Frank, Dhruv Mehra, Annika Fröhlich, Johannes W. Bagnoli, Maya C. André, Claudia D. Baldus, Martin Carroll, Christine Dierks, Martin Ebinger, Katharina S. Götze, Pablo Menéndez, Christian Récher, Ambrine Sahal, Jean-Emmanuel Sarry, Christian Thiede, Talía Velasco-Hernández, Xiaoyan Wei, Jan H. Klusmann, Wolfgang Enard, Michael von Bergwelt-Baildon, Wolfgang Hiddemann, Klaus H. Metzeler, Philipp A. Greif, Michael Heuser, Daniel B. Lipka, Marion Subklewe, Sebastian Vosberg, Tobias Herold, Karsten Spiekermann, Irmela Jeremias

  • October 5, 2026

Related Content

Correction to “Combined inhibition of de novo pyrimidine synthesis and ATR promotes ATF4-mediated cell death in TP53-deficient ALL”

  • October 5, 2026

The Keys to Opening Access to Clinical Trials

Thyroid Cancer: What Are the Latest Advances in Treatment?

Thyroid cancer is usually a highly treatable malignancy with overall five-year survival rates over 98%. Many patients with thyroid cancer go on to live for several decades after their disease is cured. 

  • by

  • September 29, 2026

  • 6 min